Phase 2 Trial of Triple Combo in Treating Advanced Breast Cancer Opening, Zymeworks Says

Phase 2 Trial of Triple Combo in Treating Advanced Breast Cancer Opening, Zymeworks Says
Zymeworks announced the start of a Phase 2 trial examining its experimental cancer treatment ZW25, in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and the hormone therapy Faslodex (fulvestrant), in people with advanced breast cancer. An agreement with Pfizer to make Ibrance available to the Zymeworks-sponsored study helped to move it forward. The trial (NCT04224272) is recruiting up to 76 patients with locally advanced breast cancer who received prior treatment or with metastatic breast cancer. The cancer must also be positive for a hormone receptor (HR) and for the HER2 protein. The open-label, two-part trial is now enrolling at South Texas Accelerated Research Therapeutics in San Antonio, with plans to expand to additional sites in the U.S., Canada, and Spain. Information is available here. Investigators in the study's first part will evaluate the tolerability and safety of ZW25, in combination with Ibrance and Faslodex, and confirm the recommended
Subscribe or to access all post and page content.